Amgen Absorbs Horizon, Pitches Plans For New Rare Disease Growth Engine
Full-Year 2023 Guidance Raised By At Least $1bn
Now that Amgen has completed its $27.8bn acquisition of Horizon, the company can focus on how it will turn Tepezza back into a growth product and maintain momentum for Krystexxa and other assets.
